A Phase 1b Dose-Escalation Study of MEK162 in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Trial Profile

A Phase 1b Dose-Escalation Study of MEK162 in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Binimetinib (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors Array BioPharma
  • Most Recent Events

    • 11 Feb 2016 Planned primary completion date changed from 1 Jun 2014 to 1 Feb 2016 as per ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Primary endpoint has been met. (Establish the recommended Phase 2 dose of study drug)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top